This is said to occur in a small percentage of peptide therapy patients and tends to be mild, as well as transient
Diabetes Obes Metab 2018;20:88997
335,336 First reported as the first reversible METAP inhibitor (METAPi) in 2003, LAF389 is a natural benzimide compound with dual METAP 1i and METAP 2i activities
The Diabetes Treatment Satisfaction Questionnaire: DTSQ
For the total population scenarios, men were projected to see a greater benefit from both SGLT2is and GLP-1 RAs than women, resulting in lower ICERs for men (the ICERs for SGLT2is were AU$20,361 per QALY for men and AU$28,377 per QALY for women, and those for GLP-1 RAs were AU$96,021 per QALY for men and AU$107,169 per QALY for women)
Biomed Pharmacother (2019) 113:108667